Volume 30, Issue 2, February 2025

Chemotherapy adversely affects physical well-being, and inflammation may be related to changes in physical well-being. This article evaluates the association of systemic inflammation with changes in physical well-being.

Chemotherapy-induced cognitive impairment is a well-recognized side effect of breast cancer treatment. This study investigated cognitive dysfunction and its impact on quality of life and everyday functioning in patients with breast cancer receiving first-line chemotherapy compared to patients with breast cancer without chemotherapy.

This single-arm, phase II study investigated the safety of a 15-minute infusion of fosnetupitant in patients with gastrointestinal and breast cancer.

Real-world success rate of liquid and tissue-based comprehensive genomic profiling (CGP) is unknown. This study analyzed real-world pan-tumor cohorts that underwent CGP during clinical care via FoundationOne CDx and Liquid CDx to determine tissue and liquid sample adequacy based on tumor type.

Understanding molecular alterations is essential for evaluating possible targets for more effective systemic therapies for the rare malignancy penile squamous cell carcinoma.

This study assessed the safety and efficacy of the anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy in advanced urothelial carcinoma.

Claudin 18.2 (CLDN18.2) is a promising target for targeted therapies in gastric cancer. This study investigated the prevalence of CLDN18.2 expression in patients with stages II-IV gastric cancer or gastroesophageal junction adenocarcinoma and its correlation with clinicopathologic features and other crucial biomarkers.

The molecular characterization of early-stage (1-3) colorectal cancer (CRC) remains incomplete, as opposed to metastatic disease, where comprehensive genomic profiling is routinely performed. This study aimed to characterize the genomics of stages 1-3 versus 4 CRC and the genomics of patients recurring within 1 year of diagnosis.

This study focused on whether preexisting cardiovascular disease increased the odds of developing cardiovascular adverse events during Bruton tyrosine kinase inhibitor therapy.

The development of targeted and immunotherapies for lung cancer has introduced treatment complexities for health care providers. This article describes the knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as identified and discussed by prominent experts in oncology at the recent conference “Bridging the Gaps in Lung Cancer.”

This study evaluated the association of azole drugs with overall survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

This study aimed to delineate the proportion and prognosis of patients with hyperprogressive disease (HPD) receiving anti-PD-1 monotherapy and to identify patient with HPD clinical characteristics across melanoma subtypes to inform clinical decision making.

This case report provides evidence of clinical benefit from EGFR tyrosine kinase inhibitors in colorectal cancer harboring EGFR kinase domain duplication.

Healthcare professionals are faced with the new challenges of preventing and managing drug-related problems with oral anticancer therapy. This study assessed ONCORAL, a real-life multidisciplinary care plan.

This article compares the efficacy of NEPA- and aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting among cancer patients, with a particular focus on evidence garnered from randomized controlled trials.

This study investigated the efficacy and safety of radiotherapy combined with targeted therapy and immunotherapy in treating hepatocellular carcinoma and portal vein tumor thrombosis.

This study assessed tumor progression in patients with hepatocellular carcinoma without macrovascular invasion who underwent treatment with conventional transarterial chemoembolization based on microvascular invasion risk within 2 years.

This brief communication describes the case of a patient diagnosed with chronic myelomonocytic leukemia with NPM1 mutation and briefly review the literature to highlight the uncertainty about how to classify this condition.

There is little consensus on the efficacy or optimal timing of treatment in smoldering multiple myeloma (SMM). This article reviews the landscape of all clinical trials in this disease, comparing the efficacy of treatment regimens in SMM to results from these regimens when used in newly diagnosed MM.

The use of antibiotics modifies intestinal microbiota, potentially affecting treatment outcomes. This real-world study evaluated the effect of antibiotic exposure within different periods of time on the clinical outcomes of a multi-tumor cohort of patients treated with immune checkpoint inhibitors.

This article reviews the mechanism, efficacy, safety, and quality of life of Tumor Treating Fields (TTFields) therapy in glioblastoma. This unique noninvasive treatment uses a portable device to deliver electric fields to the tumor using arrays that are placed on the skin and kill cancer cells in several ways.